Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer

Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells

“…In ovarian cancers, >70% of patients initially respond to therapy with platinating agents. However, these patients often quickly develop resistance: the five-year survival rate for ovarian carcinoma is <25% (15). Resistance can develop as a result of decreased influx or increased efflux of drug (MDR, LRP), glutathione or metallothionein conjugation (GST-π), drug detoxification, DNA repair, or skipping lesions during DNA replication (ERCC1), and inhibition of apoptosis (5,6).…”

Safety and efficacy of salvage nano-particle albumin bound paclitaxel in recurrent cervical cancer: A feasibility study

“…In this series, NAB-paclitaxel was the most effective agent demonstrating a partial response in 10 of 35 subjects (28.6 %). An additional 15 subjects experienced stable disease (42.9 %) [14,15].…”

“…In this heavily pre-treated population with prior radiation, where disease is not amenable to surgical excision, there has been an evolution in cytotoxic chemotherapy regimens [1]. Gynecologic Oncology Group (GOG) protocol 204 established double therapy of cisplatin and paclitaxel as the standard of care.…”

Cervical neoplasia in pregnancy. Part 2: current treatment of invasive disease

“…Treatment guidelines for the nongravid patient with invasive squamous cell carcinoma of the cervix have been developed through a series of well-designed, randomized trials. 25,26 In such patients, the decision to proceed with either surgical excision or radiation with chemotherapy is based almost exclusively on the clinically determined stage. With the notable exception of very early lesions, the treatment options lead to sterility, either by removal or destruction of the organs responsible for the reproductive function.…”